Fudan University Shanghai Cencer Center
Welcome,         Profile    Billing    Logout  
 1 Trial 
7 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Luo, Zhiguo
MTAM, NCT04472806: Maintenance Treatment of Toripalimab(JS001) in Patients With Unresectable Locally Advanced or Metastatic Mucosal Melanoma

Recruiting
2
31
RoW
Toripalimab, JS001, chemotherapy in combination with Endostar
Fudan University, Zhejiang Cancer Hospital, Fujian Cancer Hospital, The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Mucosal Melanoma
06/22
06/23
NCT06699472: A Prospective, Randomized, Controlled Clinical Study on the Prevention of Chemotherapy Related Myelosuppression in Patients with Ewing's Sarcoma Using Trilaciclib

Recruiting
2
22
RoW
Chemotherapy, VDC/IE alternating chemotherapy, Trilaciclib Injection [Cosela]
Fudan University
Ewing Sarcoma, Myelosuppression
09/26
09/27
NCT06694324: First-line Treatment of Advanced/unresectable DDLPS

Not yet recruiting
2
49
RoW
Liposomal Doxorubicin (Doxil), Apatinib, Camrelizumab
Fudan University
Dedifferentiated Liposarcoma, Soft Tissue Sarcoma (STS)
06/26
12/26
NCT06869174: Pucotenlimab Combined with MRG002 for HER2-positive Cancer of Unknown Primary

Not yet recruiting
2
50
RoW
Pucotenlimab combined with MRG002
Zhiguo Luo, MD, PhD
Cancer of Unknown Primary
03/27
08/28
NCT06041724: Envafolimab Combined With Recombinant Human Endostatin and First-line Chemotherapy Treat of Advanced Mucosal Melanoma

Not yet recruiting
2
46
NA
Envafolimab combined with recombinant human endostatin and first-line chemotherapy
Fudan University
Advanced Mucosal Melanoma
09/25
03/26
NCT04773951: A Phase I Study to Evaluate the Safety, Tolerability and Pharmacokinetics of JS004 in Advanced Solid Tumors

Recruiting
1
156
RoW
JS004, a recombinant humanized, IgG4κ monoclonal antibody (mAb) specific to B- and T-lymphocyte attenuator (BTLA); Toripalimab Injection
Shanghai Junshi Bioscience Co., Ltd.
Melanoma, Renal Carcinoma, Urothelial Carcinoma
02/24
08/24
NCT04952103: Real World Study of Diagnosis and First-line Treatment Among Patients With Cancer of Unknown Primary in China

Recruiting
N/A
200
RoW
no intervention
Fudan University
Cancer of Unknown Primary Site
06/23
06/24
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Luo, Zhiguo
MTAM, NCT04472806: Maintenance Treatment of Toripalimab(JS001) in Patients With Unresectable Locally Advanced or Metastatic Mucosal Melanoma

Recruiting
2
31
RoW
Toripalimab, JS001, chemotherapy in combination with Endostar
Fudan University, Zhejiang Cancer Hospital, Fujian Cancer Hospital, The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Mucosal Melanoma
06/22
06/23
NCT06699472: A Prospective, Randomized, Controlled Clinical Study on the Prevention of Chemotherapy Related Myelosuppression in Patients with Ewing's Sarcoma Using Trilaciclib

Recruiting
2
22
RoW
Chemotherapy, VDC/IE alternating chemotherapy, Trilaciclib Injection [Cosela]
Fudan University
Ewing Sarcoma, Myelosuppression
09/26
09/27
NCT06694324: First-line Treatment of Advanced/unresectable DDLPS

Not yet recruiting
2
49
RoW
Liposomal Doxorubicin (Doxil), Apatinib, Camrelizumab
Fudan University
Dedifferentiated Liposarcoma, Soft Tissue Sarcoma (STS)
06/26
12/26
NCT06869174: Pucotenlimab Combined with MRG002 for HER2-positive Cancer of Unknown Primary

Not yet recruiting
2
50
RoW
Pucotenlimab combined with MRG002
Zhiguo Luo, MD, PhD
Cancer of Unknown Primary
03/27
08/28
NCT06041724: Envafolimab Combined With Recombinant Human Endostatin and First-line Chemotherapy Treat of Advanced Mucosal Melanoma

Not yet recruiting
2
46
NA
Envafolimab combined with recombinant human endostatin and first-line chemotherapy
Fudan University
Advanced Mucosal Melanoma
09/25
03/26
NCT04773951: A Phase I Study to Evaluate the Safety, Tolerability and Pharmacokinetics of JS004 in Advanced Solid Tumors

Recruiting
1
156
RoW
JS004, a recombinant humanized, IgG4κ monoclonal antibody (mAb) specific to B- and T-lymphocyte attenuator (BTLA); Toripalimab Injection
Shanghai Junshi Bioscience Co., Ltd.
Melanoma, Renal Carcinoma, Urothelial Carcinoma
02/24
08/24
NCT04952103: Real World Study of Diagnosis and First-line Treatment Among Patients With Cancer of Unknown Primary in China

Recruiting
N/A
200
RoW
no intervention
Fudan University
Cancer of Unknown Primary Site
06/23
06/24

Download Options